A Comparative, Open-label, Parallel Design, Bioavailability Study of Two Misoprostol Formulations (Angusta™ 25 µg Dispersible Tablets vs. Cytotec® 200 µg Tablets) Following Single Oral or Sublingual Administration and Comparison of Safety of the Two Formulations Following Repeat Dosing Until Labour
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Region Skane
- 入组人数
- 72
- 试验地点
- 1
- 主要终点
- AUC (area under the curve) 0-t misoprostol
研究概览
简要总结
The purpose of this study is to compare pharmacokinetics of two formulations of misoprostol following single dose administration in adult women being given misoprostol for cervical ripening and induction of labour.
详细描述
Prostaglandin E2 (dinoprostone) given vaginally or intra-cervically, and oxytocin have been the most commonly used preparations for induction of labour. Misoprostol is a synthetic prostaglandin E1 analogue. Misoprostol has anti-secretory and mucosal protective properties and was originally developed in the 1970s for the prevention of nonsteroidal anti-inflammatory drug (NSAID)-induced peptic ulcers. It is now used much more widely for 'off-label' indications like medication abortion, medical management of miscarriage, cervical ripening before surgical procedures, treatment of postpartum hemorrhage, and induction of labour. The lack of a specific license for Cytotec® to be used in obstetrics and gynecology has led to a number of problems regarding correct dose and dose regime.
The study is an open-label, randomized, single-dose, comparative, parallel design, bioavailability study followed by repeat dosing of of two formulations misoprostol in healthy adult females being induced to go into labour.
The drug shall be administered orally or sublingually.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Adult females
- •Women wanting to participate and having given informed consent
- •Known to have reached week 37 + 0 days to week 42 + 2 days of gestation
- •With a viable fetus in a vertex position
- •Age above or equal to 18 years old
- •Women opting for vaginal delivery
- •BMI between 20 and 30 kg/m2
排除标准
- •Women with known allergy to misoprostol or other prostaglandins
- •Women with prior caesarean section
- •Women with dead or anomalous fetus
- •Women with twin pregnancy
- •Women with known liver or renal dysfunction
研究组 & 干预措施
Oral (A)
One tablet of Angusta™ (25 µg) or 1/8 of a tablet of Cytotec® (25 µg).
干预措施: Angusta™ (Drug)
Oral (A)
One tablet of Angusta™ (25 µg) or 1/8 of a tablet of Cytotec® (25 µg).
干预措施: Cytotec® (Drug)
Oral (B)
Two tablets of Angusta™ 25 µg or ¼ of a tablet of Cytotec®.
干预措施: Angusta™ (Drug)
Oral (B)
Two tablets of Angusta™ 25 µg or ¼ of a tablet of Cytotec®.
干预措施: Cytotec® (Drug)
Sublingual (C)
Two tablets of Angusta™ (total dose of 50 µg) or ¼ of a tablet of Cytotec® (50 µg.
干预措施: Angusta™ (Drug)
Sublingual (C)
Two tablets of Angusta™ (total dose of 50 µg) or ¼ of a tablet of Cytotec® (50 µg.
干预措施: Cytotec® (Drug)
结局指标
主要结局
AUC (area under the curve) 0-t misoprostol
时间窗: For 2 hours regime: pre-dose, 5, 10, 20, 30, 40, 50, 75, 100 and 120 min post-dose. For 4-hours regime at pre-dose, 5, 10, 20, 30, 40, 50, 75, 100,120, 180 and 240 min post-dose
AUC (area under the curve) 0-inf of misoprostol
时间窗: For 2 hours regime: pre-dose, 5, 10, 20, 30, 40, 50, 75, 100 and 120 min post-dose. For 4-hours regime at pre-dose, 5, 10, 20, 30, 40, 50, 75, 100,120, 180 and 240 min post-dose
次要结局
- t max (Time to maximum) of misoprostol(For 2 hours regime: pre-dose, 5, 10, 20, 30, 40, 50, 75, 100 and 120 min post-dose. For 4-hours regime at pre-dose, 5, 10, 20, 30, 40, 50, 75, 100,120, 180 and 240 min post-dose)
- t 1/2 (Elimination half-life) of misoprostol(For 2 hours regime: pre-dose, 5, 10, 20, 30, 40, 50, 75, 100 and 120 min post-dose. For 4-hours regime at pre-dose, 5, 10, 20, 30, 40, 50, 75, 100,120, 180 and 240 min post-dose)
- APGAR score of infant(At time of birth)
- Adverse event / Serious Adverse event profile.(From screening and until 7 days post treatment.)
- Cardiotochographic (CTG) monitoring.(During labour)